Figueras Aloy, J <br/><br/>
[Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].  [electronic resource] 

 -  Anales de pediatria (Barcelona, Spain : 2003)  Aug 2010 
 - 98.e1-4 p.  digital 
<br/><br/> Publication Type: English Abstract; Journal Article; Practice Guideline 
<br/><br/><label>ISSN: </label>1695-9531 
<br/><br/><label>Standard No.: </label>10.1016/j.anpedi.2010.05.026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antiviral Agents--therapeutic use<br/>Gestational Age<br/>Humans<br/>Infant, Newborn<br/>Infant, Premature, Diseases--prevention & control<br/>Palivizumab<br/>Respiratory Syncytial Virus Infections--prevention & control